← Back to Search

Illuccix Total Body PET-CT for Prostate Cancer

Phase < 1
Recruiting
Research Sponsored by BAMF Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Summary

This trial will use Illuccix to establish a standard scanning protocol for PET-CT imaging on the United Imaging scanner uEXPLORER.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Comparing the imaging quality using low dose and high dose Ga-68 PSMA-11 at various scan lengths.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Low DoseExperimental Treatment1 Intervention
3 mCi dose of 68Ga-PSMA-11 (Illuccix) and a total body PET-CT scan for 4-6 min scan time.
Group II: High doseExperimental Treatment1 Intervention
7 mCi dose of 68Ga-PSMA-11 (Illuccix) and a total body PET-CT scan for 4-6 min scan time.

Find a Location

Who is running the clinical trial?

Telix Pharmaceuticals (Innovations) Pty LimitedIndustry Sponsor
18 Previous Clinical Trials
1,297 Total Patients Enrolled
2 Trials studying Prostate Cancer
115 Patients Enrolled for Prostate Cancer
BAMF HealthLead Sponsor
1 Previous Clinical Trials
30 Total Patients Enrolled
Telix International Pty LtdIndustry Sponsor
18 Previous Clinical Trials
1,218 Total Patients Enrolled
2 Trials studying Prostate Cancer
115 Patients Enrolled for Prostate Cancer

Media Library

Low Dose Clinical Trial Eligibility Overview. Trial Name: NCT05558956 — Phase < 1
Prostate Cancer Research Study Groups: Low Dose, High dose
Prostate Cancer Clinical Trial 2023: Low Dose Highlights & Side Effects. Trial Name: NCT05558956 — Phase < 1
Low Dose 2023 Treatment Timeline for Medical Study. Trial Name: NCT05558956 — Phase < 1
~37 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top